These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 26799539

  • 1. Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
    Hallberg S, Banefelt J, Fox KM, Mesterton J, Johansson G, Levin LÅ, Sobocki P, Gandra SR.
    Int J Clin Pract; 2016 Mar; 70(3):222-8. PubMed ID: 26799539
    [Abstract] [Full Text] [Related]

  • 2. Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden.
    Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LÅ, Sobocki P, Gandra SR.
    Eur J Health Econ; 2016 Dec; 17(9):1117-1124. PubMed ID: 26607457
    [Abstract] [Full Text] [Related]

  • 3. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.
    Hallberg S, Gandra SR, Fox KM, Mesterton J, Banefelt J, Johansson G, Levin LÅ, Sobocki P.
    Eur J Health Econ; 2016 Jun; 17(5):591-601. PubMed ID: 26077550
    [Abstract] [Full Text] [Related]

  • 4. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register.
    Hero C, Karlsson SA, Franzén S, Svensson AM, Miftaraj M, Gudbjörnsdottir S, Andersson Sundell K, Eliasson B, Eeg-Olofsson K.
    BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958300
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
    Jacobson TA, Wertz DA, Kuznik A, Cziraky M.
    Curr Med Res Opin; 2013 Jul; 29(7):773-81. PubMed ID: 23647370
    [Abstract] [Full Text] [Related]

  • 6. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A.
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [Abstract] [Full Text] [Related]

  • 7. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
    Svensson MK, Sorio Vilela F, Leósdóttir M, Banefelt J, Lindh M, Dun AR, Norhammar A, Villa G.
    Ups J Med Sci; 2022 Dec; 127():. PubMed ID: 35722183
    [Abstract] [Full Text] [Related]

  • 8. Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study.
    Ho CLB, Chowdhury EK, Breslin M, Doust J, Reid CM, Wing LMH, Nelson MR, 2nd Australian National Blood Pressure Study Management Committee.
    J Clin Lipidol; 2019 Dec; 13(1):148-155. PubMed ID: 30293937
    [Abstract] [Full Text] [Related]

  • 9. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
    Devine J, Linton A, Mistry H, Napier J, Trice S, Bacon T.
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
    [Abstract] [Full Text] [Related]

  • 10. Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.
    Punekar RS, Fox KM, Paoli CJ, Richhariya A, Cziraky MJ, Gandra SR, Toth PP.
    Curr Med Res Opin; 2017 May; 33(5):869-876. PubMed ID: 28276256
    [Abstract] [Full Text] [Related]

  • 11. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
    Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Holme I, Semb AG.
    Ann Rheum Dis; 2015 Aug; 74(8):1544-50. PubMed ID: 24699940
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy.
    Galema-Boers AM, Lenzen MJ, Engelkes SR, Sijbrands EJ, Roeters van Lennep JE.
    J Clin Lipidol; 2018 Aug; 12(2):409-416. PubMed ID: 29398430
    [Abstract] [Full Text] [Related]

  • 13. Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes.
    Hero C, Karlsson SA, Franzén S, Svensson AM, Miftaraj M, Gudbjörnsdottír S, Andersson-Sundell K, Eliasson B, Eeg-Olofsson K.
    Diabetes Ther; 2021 Sep; 12(9):2371-2386. PubMed ID: 34292559
    [Abstract] [Full Text] [Related]

  • 14. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.
    Karlsson SA, Hero C, Svensson AM, Franzén S, Miftaraj M, Gudbjörnsdottir S, Eeg-Olofsson K, Eliasson B, Andersson Sundell K.
    BMJ Open; 2018 Mar 30; 8(3):e020309. PubMed ID: 29602853
    [Abstract] [Full Text] [Related]

  • 15. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.
    Kim S, Kim H, Kim E, Han S, Rane PP, Fox KM, Zhao Z, Qian Y, Suh HS.
    Clin Ther; 2018 Jun 30; 40(6):940-951.e7. PubMed ID: 29735297
    [Abstract] [Full Text] [Related]

  • 16. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden.
    Karlsson SA, Eliasson B, Franzén S, Miftaraj M, Svensson AM, Andersson Sundell K.
    BMJ Open Diabetes Res Care; 2019 Jun 30; 7(1):e000639. PubMed ID: 31114701
    [Abstract] [Full Text] [Related]

  • 17. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.
    Hero C, Rawshani A, Svensson AM, Franzén S, Eliasson B, Eeg-Olofsson K, Gudbjörnsdottir S.
    Diabetes Care; 2016 Jun 30; 39(6):996-1003. PubMed ID: 27208327
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N, ASCOT Investigators.
    J Am Coll Cardiol; 2013 Aug 20; 62(8):717-29. PubMed ID: 23948514
    [Abstract] [Full Text] [Related]

  • 19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 20; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan 20; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.